<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418844</url>
  </required_header>
  <id_info>
    <org_study_id>VIVROVAIRE TR</org_study_id>
    <nct_id>NCT03418844</nct_id>
  </id_info>
  <brief_title>Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy</brief_title>
  <acronym>VIVROVAIRE TR</acronym>
  <official_title>Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While they are documented in patients in remission of testicular cancer, the sequelae of
      chemotherapy and the impact of the disease and its treatments on the living conditions and
      QoL of women in remission of rare ovarian cancer remain poorly explored.

      The coordinator therefore propose a national 2-step case-control study to evaluate 1) chronic
      fatigue and QoL and 2) chemotherapy-related sequelae in adult patients in remission of
      surgery-treated TGMO or TSCS (conservative or not) supplemented with chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients and healthy volunteers will complete several self-questionnaires on living conditions and quality of life. Patients will also perform a cardiac, pulmonary, auditory and biological assessment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The chronic fatigue by questionnaires</measure>
    <time_frame>2 years after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The late sequelae of chemotherapy, particularly cardiovascular and pulmonary disorders, in adult patients in remission of a rare cancer of the ovary treated by surgery, supplemented or not by chemotherapy.</measure>
    <time_frame>2 years after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The quality of life by questionnaires</measure>
    <time_frame>2 years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The fertility monitoring by questionnaires</measure>
    <time_frame>2 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The symptoms of menopause by questionnaires</measure>
    <time_frame>2 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theimpact of cancer and its treatments on the trajectory and professional situation by questionnaires(access to work, professional ambition, financial situation ...);</measure>
    <time_frame>2 years after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The parental projects by age (≤ 45 years) by questionnaires</measure>
    <time_frame>2 years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Germ Cell Tumor</condition>
  <condition>Sex Cord Stromal Tumor</condition>
  <condition>Malignant Non-epithelial Ovarian Tumors</condition>
  <arm_group>
    <arm_group_label>Interest group (patients treated with chemotherapy)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient control group (patients not treated with chemotherapy)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self-questionnaires of living conditions and quality of life</intervention_name>
    <description>Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)</description>
    <arm_group_label>Interest group (patients treated with chemotherapy)</arm_group_label>
    <arm_group_label>Patient control group (patients not treated with chemotherapy)</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac, pulmonary, auditory and biological assessment</intervention_name>
    <description>Patients will perform :
Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D with Dobutamine injection)
Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)
Blood tests</description>
    <arm_group_label>Interest group (patients treated with chemotherapy)</arm_group_label>
    <arm_group_label>Patient control group (patients not treated with chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18 years;

          -  Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or
             sex cords (TSCS) treated optimally;

          -  Patient who has had surgery and chemotherapy (interest group) or only a surgery
             (control group);

          -  Patient in remission more than 2 years after the end of the initial treatment;

          -  Relapse authorized if remission more than 2 years after the end of the treatment;

          -  Patient with no other cancers (with the exception of basal cell skin carcinomas, in
             situ cancers of the breast and cervix);

          -  Patient having signed his consent to participate

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman;

          -  Psychiatric pathology that may disrupt the course of the study or prevent the
             interpretation of results;

          -  Person deprived of liberty;

          -  Major subject to a legal protection measure or unable to express his consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence JOLY, PhD</last_name>
    <phone>33 2 31 45 50 02</phone>
    <email>f.joly@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besançon Jean MINJOZ</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa KALBACHER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elsa KALBACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando BAZAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin DEMARCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura MANSI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne FLOQUET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne FLOQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic GUYON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille CHAKIBA-BRUGERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Fleyriat</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert ORFEUVRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hubert ORFEUVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe POMEL, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe POMEL, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle RAY-COQUARD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle RAY-COQUARD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine ROUSSET-JABLONSKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Etienne HEUDEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline ROCHEFORT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi BRAHMI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magali PROVENSAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Magali PROVENSAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celia BECUWE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Celia BECUWE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique SPAETH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabien BROCARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imane BOUALLAGUI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain LORTHOLARY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain LORTHOLARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude EL KOURI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorothée CHOCTEAU-BOUJU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène CASTANIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin LINOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique BERTON-RIGAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique BERTON-RIGAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle BOURBOULOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole GOURMELON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Sebastien FRENEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie ROBERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GH Cochin Broca Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure DE COCK, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laure DE COCK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Emmanuel KURTZ, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cedric NADEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cedric NADEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aude-Marie SAVOYE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aude-Marie SAVOYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Rennais de Cancérologie</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibault DE LA MOTTE ROUGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thibault DE LA MOTTE ROUGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Stasbourg Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure DE COCK, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laure DE COCK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Emmanuel KURTZ, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenael FERRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gwenael FERRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandra MARTINEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion DESLANDRES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence GLADIEFF, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Sex Cord-Gonadal Stromal Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

